In 2012, advances in molecular profiling of primary brain tumours allowed identification of subgroups of glioma and medulloblastoma that were associated with distinct prognoses and predicted treatment response. Adjuvant chemotherapy is now established for 1p/19q co-deleted anaplastic oligodendrogliomas, and may be the preferred treatment in elderly patients with glioblastoma with a methylated MGMT promoter.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wick, W. et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 13, 707–715 (2012).
Malmström, A. et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 13, 916–926 (2012).
van den Bent, M. J. et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2012.43.2229.
Shaw, E. G. et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J. Clin. Oncol. 30, 3065–3070 (2012).
Chinot, O. et al. Roche study showed that Avastin helped people with newly diagnosed gliobastoma live longer without their disease worsening when added to radiation and chemotherapy. F. Hoffmann-La Roche Ltd, [online] (2012).
Stupp, R. et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur. J. Cancer 48, 2192–2202 (2012).
Choi, C. et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat. Med. 18, 624–629 (2012).
Northcott, P. A., Korshunov, A., Pfister, S. M. & Taylor, M. D. The clinical implications of medulloblastoma subgroups. Nat. Rev. Neurol. 8, 340–351 (2012).
Robinson, G. et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 488, 43–48 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R. Stupp served on Advisory Boards to MSD (Merck & Co.), Merck Serono (EMD), and Roche. He is the principal investigator of phase III trials investigating Cilengitide (Merck Serono) and the NovoTTF device (NovoCure Ltd) in glioblastoma. M. E. Hegi served on Advisory Boards to MSD (Merck & Co.), Merck Serono (EMD), and MDxHealth.
Rights and permissions
About this article
Cite this article
Stupp, R., Hegi, M. Molecular characterization leads the way. Nat Rev Clin Oncol 10, 69–70 (2013). https://doi.org/10.1038/nrclinonc.2012.240
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2012.240
This article is cited by
-
Silencing of histone deacetylase 2 suppresses malignancy for proliferation, migration, and invasion of glioblastoma cells and enhances temozolomide sensitivity
Cancer Chemotherapy and Pharmacology (2016)
